ArticleParasites & vectors2011
Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy.
Article in Parasites & vectors, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 66 citations in OpenAlex.
- Phytochemical Characterization, Molecular Docking Analysis, and In Vitro Antischistosomal Activity of Capsicum annuum Methanolic Extract.Chemistry & biodiversity · 2026Article
- Efficacy assessment of miltefosine and curcumin againstAntimicrobial agents and chemotherapy · 2024Article
- Evaluation of the prophylactic and therapeutic efficacies of mucus and tissue nucleoproteins extracted fromJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Molluscicidal and Larvicidal Potency ofPharmaceutics · 2023Article
- Myco-Synthesized Molluscicidal and Larvicidal Selenium Nanoparticles: A New Strategy to ControlJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.Parasites & vectors · 2020Article
- A Review of Nanotechnology for Targeted Anti-schistosomal Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- Reviewing the Effects of Miltefosine and Suggesting It for the Treatment of Coronavirus Disease (COVID-19).Infectious diseases · 2020Review
- Paenidigyamycin A, Potent Antiparasitic Imidazole Alkaloid from the GhanaianMarine drugs · 2018Article
- The potential effects of silver and gold nanoparticles as molluscicides and cercaricides on Schistosoma mansoni.Parasitology research · 2018Article
- Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens.PLoS neglected tropical diseases · 2017Article
- In Vitro Assessment of Anthelmintic Activities ofJournal of parasitology research · 2017Article
- Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.PloS one · 2015Article
- Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel.PLoS neglected tropical diseases · 2015Article
- Repurposing drugs for the treatment and control of helminth infections.International journal for parasitology. Drugs and drug resistance · 2014Review
- Miltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity.Antimicrobial agents and chemotherapy · 2014Article
- Laboratory assessment of molluscicidal and cercariacidal effects of Glinus lotoides fruits.BMC research notes · 2014Article
- Evaluation of the effect of miltefosine on Trichomonas vaginalis.Parasitology research · 2014Article
- In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMiltefosine, which is the first oral drug licensed for the treatment of leishmaniasis, was recently reported to be a promising lead compound for the synthesis of novel antischistosomal derivatives with potent activity in vivo against different developmental stages of Schistosoma mansoni. In this paper an in vitro study was carried out to investigate whether it has a biocidal activity against the aquatic stages of Schistosoma mansoni and its snail intermediate host, Biomphalaria alexandrina , thus being also a molluscicide. Additionally, to see whether miltefosine can have a broad spectrum antischistosomal activity, a similar in vitro study was carried out on the adult stage of Schistosoma haematobium, the second major human species, its larval stages and snail intermediate host, Bulinus truncutes. This was checked by scanning electron microscopy.
resultsMiltefosine proved to have in vitro ovicidal, schistolarvicidal and lethal activity on adult worms of both Schistosoma species and has considerable molluscicidal activity on their snail hosts. Scanning electron microscopy revealed several morphological changes on the different stages of the parasite and on the soft body of the snail, which further strengthens the current evidence of miltefosine's activity. This is the first report of mollusicidal activity of miltefosine and its in vitro schistosomicidal activity against S.haematobium.
conclusionsThis study highlights miltefosine not only as a potential promising lead compound for the synthesis of novel broad spectrum schistosomicidal derivatives, but also for molluscicidals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.